Schizophrenia: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• NMDA 9
• BDNF 0
• GLP-1 1
• mTOR 0
• AKT 0
• PI3K 0
• TNF 0
• ERK 0
• IL-6 0
• NLRP3 0
• PPAR 0
• NRF2 0
• AMPK 0
• IL-17 0
• IL-23 1
• MAPK 0
• MAPT 0
• BACE1 0
• BCL-2 0
• C9orf72 0
• CD20 0
• COX-2 0
• DMD 0
• EGFR 0
• FOXP3 0
• FTO 0
• HMGB1 0
• IDO1 0
• IL-1 0
• JAK 0
• MMP-9 0
• PCSK9 0
• PDE4 0
• SCN2A 0
• SGLT2 0
• SIRT1 0
• STAT3 0
• TFEB 0
• TREM2 0
• VEGF 0

1 of 1+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Misinterpreting reality: Investigating the neural basis of hallucinatory percepts (MISHAPS)

  University College London· London, United Kingdom· EU contribution €260,348· until Aug 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Interneuron subtype-specific control of hippocampal memory encoding and retrieval (INSPIRE)

  Universitaetsklinikum Freiburg· Freiburg, Germany· EU contribution €202,125· until Aug 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Continuous Estrogen Monitoring Patch (EstroPatch)

  Katholieke Universiteit Leuven· Leuven, Belgium· EU contribution €321,301· until May 2030· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Cannabis Neurobiology And Schizophrenia Risk in Youth: A Multi-Omics Translation (CANARY)

  Karolinska Institutet· Stockholm, Sweden· EU contribution €1,500,000· until Dec 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Thalamic Nuclei Connectivity in the Psychosis Continuum: Parsing Clinical Heterogeneity and Individual Trajectories (THALAMIND)

  Universite de Geneve· Geneve, Switzerland· EU contribution €469,989· until Dec 2029· 2 countries

5 of 52 running projects, newest first. Listed amounts together: €125.4m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 8
• Organoids 5
• Mendelian Randomization Analysis 70
• CRISPR-Cas Systems 2
• Gene Expression Profiling 45
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 3
• Exome Sequencing 4
• Proteomics 30
• Metabolomics 24
• Mass Spectrometry 7
• Flow Cytometry 1
• Immunohistochemistry 8
• Positron-Emission Tomography 30
• Magnetic Resonance Imaging 385
• Machine Learning 81
• Deep Learning 17
• Cohort Studies 169
• Genome-Wide Association Study 174

• Genetic architecture of postpartum psychosis: from common to rare genetic variation.

  Mol Psychiatry, May 2026

• Complete genome and comparative genomic analysis of cefpodoxime resistant Pantoea septica strain GABEPS69 isolated from saliva of a patient diagnosed with treatment resistant schizophrenia.

  Int J Med Microbiol, Oct 2025

• Whole genome sequence study of cannabis dependence in two independent cohorts.

  Addict Biol, Jan 2017

See which targets of this disease your abstract mentions, and go to the people working on them.